论文部分内容阅读
由于增加癌症患者的死亡风险、肿瘤进展及血栓栓塞风险,欧盟人用药品委员会(CHMP)决定修改EPO(促红细胞生成素)类产品的说明书。两项临床研究结果均显示癌症患者的死亡率增加。一项为NeoRecormon(罗氏公司的促红细
The European Commission on Human Medicines (CHMP) has decided to revise the EPO (erythropoietin) -based product due to its increased risk of death from cancer, tumor progression and the risk of thromboembolism. Both clinical studies have shown an increase in mortality from cancer patients. One for NeoRecormon (Roche redness